Skip to main content
Terug
Watch Compare

INOVIO PHARMACEUTICALS, INC.

Datakwaliteit: 100%
INO
Nasdaq Manufacturing Chemicals
€ 1,07
▼ € 0,02 (-1,83%)
Marktkapitalisatie: 87,30 M
Prijs
€ 1,07
Marktkapitalisatie
87,30 M
Dagbereik
€ 1,06 — € 1,11
52-Weeksbereik
€ 1,05 — € 2,98
Volume
2.589.820
Openen € 1,09
50D / 200D Gem.
€ 1,64
34,94% below
50D / 200D Gem.
€ 1,92
44,33% below

Quick Summary

Belangrijkste Punten

Revenue declined -56,20% annually over 5 years
Negative free cash flow of -88,92 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 13,79%
Capital intensive — 437,23% of revenue goes to capex

Groei

Revenue Growth (5Y)
-56,20%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-69,99%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-816,36%
Onder sectorgemiddelde (-53,41%)
ROIC-380,05%
Net Margin-130000,00%
Op. Margin-132871,32%

Veiligheid

Debt / Equity
N/A
Current Ratio0,79
Interest CoverageN/A

Waardering

PE (TTM)
-1,03
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B — 1,6
ROE % -816,4 -53,4
Net Margin % -130000,0 -41,5
Rev Growth 5Y % -56,2 1,8
D/E — 0,3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -69,99% Revenue Growth (3Y) -71,98%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -56,20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 65.343,0 Net Income (TTM) -84,95 M
ROE -816,36% ROA -123,44%
Gross Margin N/A Operating Margin -132871,32%
Net Margin -130000,00% Free Cash Flow (TTM) -88,92 M
ROIC -380,05% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,79
Interest Coverage N/A Asset Turnover 0,00
Working Capital -14,64 M Tangible Book Value -7,72 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,03 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1336,08
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -101,85%
Market Cap 87,30 M Enterprise Value 50,74 M
Per Share
EPS (Diluted TTM) -1,81 Revenue / Share 0,00
FCF / Share -1,09 OCF / Share -1,09
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 437,23% FCF Conversion 104,67%
SBC-Adj. FCF -93,15 M Growth Momentum -13,79

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 65.343,0 217.756,0 832.010,0 10,26 M 1,77 M
Net Income -84,95 M -107,25 M -135,12 M -279,82 M -303,66 M
EPS (Diluted) -1,81 -3,95 -6,09 -1,17 -1,45
Gross Profit — — — — —
Operating Income -86,82 M -112,40 M -143,94 M -267,57 M -301,22 M
EBITDA — — — — —
R&D Expenses 54,21 M 75,62 M 86,68 M 187,65 M 249,24 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 0,0 177.833,0 1,22 M 1,25 M 1,94 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 74,31 M 113,20 M 170,95 M 348,53 M 495,94 M
Total Liabilities 50,21 M 44,69 M 53,60 M 126,17 M 96,27 M
Shareholders' Equity 24,10 M 68,50 M 117,35 M 222,36 M 399,67 M
Total Debt — — — — —
Cash & Equivalents 44,27 M 65,81 M 14,31 M 46,33 M 71,14 M
Current Assets 61,12 M 97,83 M 153,11 M 315,24 M 448,44 M
Current Liabilities 43,67 M 35,33 M 42,57 M 96,87 M 65,74 M